Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: I-START Clear all
Recruiting Phase 1 Interventional

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

NCT05389423
View directory record Official record
Conditions
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
Interventions
Vincristine, Prednisone, Doxorubicin, Etoposide, Pomalidomide, Cyclophosphamide, Rituximab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT00004862
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT00667615
View directory record Official record
Conditions
Hodgkin's Disease, Lymphoma
Interventions
rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

NCT02470910
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 31, 2026, 3:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

NCT01218867
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Melanoma, Renal Cancer
Interventions
Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 31, 2026, 3:51 PM EDT
Not yet recruiting Not applicable Interventional

The PIONEER Comparative Effectiveness Study - Project 2

NCT07829107
View directory record Official record
Conditions
Head Injury Trauma, Traumatic Brain Injury, Mild
Interventions
Clinical pathway 1: Guidelines plus biomarkers, Clinical guidelines only
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Sylmar, California • Torrance, California • Clinton Township, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

NCT01876212
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
DC vaccine, Dasatinib
Biological · Drug
Lead sponsor
Walter J. Storkus
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

NCT00601692
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer

NCT00052429
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer

NCT01880528
View directory record Official record
Conditions
Dyspnea, Non-small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
lisinopril, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 31, 2026, 3:51 PM EDT
Withdrawn Phase 1 Interventional

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

NCT05228249
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Loncastuximab Tesirine, Melphalan
Procedure · Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 31, 2026, 3:51 PM EDT
Recruiting Phase 3 Interventional

Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries

NCT04979338
View directory record Official record
Conditions
Gender Dysphoria
Interventions
Ultrasound guided Continuous Infraclavicular Brachial Plexus Block, Ultrasound guided Continuous Femoral Nerve Block, Ultrasound guided Pudendal Nerve Block, Bupivacaine, Bilateral ultrasound guided Transversus Abdominis Plane Block, Bilateral spermatic cord block, Pecs I & II Block, Local anesthetic
Other · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 31, 2026, 3:51 PM EDT
Withdrawn Not applicable Interventional

A Pilot Study of Deep Brain Stimulation of the Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder

NCT01658748
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS, Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
25 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV

NCT01535885
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Adenovirus, Cytomegalovirus Infections
Interventions
Cytotoxic T Lymphocytes
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 22 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 31, 2026, 3:51 PM EDT
Completed No phase listed Observational

Back in the Game: An Immediate Functional Progression Program in Athletes With a Spondylolysis.

NCT03237104
View directory record Official record
Conditions
Low Back Pain, Spondylosis
Interventions
Immediate PT
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Columbus, Ohio • Dublin, Ohio • New Albany, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 31, 2026, 3:51 PM EDT
Withdrawn Phase 2 Interventional

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

NCT04989283
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, External Beam Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pemetrexed, Positron Emission Tomography, Therapeutic Conventional Surgery
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
46
States / cities
Jonesboro, Arkansas • Tampa, Florida • Boise, Idaho + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00005792
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
etoposide phosphate, melphalan, topotecan, Autologous Stem Cell Rescue
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 69 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

NCT01904136
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Therapy-Related Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide, Fludarabine, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 31, 2026, 3:51 PM EDT
Recruiting Not applicable Interventional

Nutrition Awareness Among Women With Non-Metastatic Breast Cancer

NCT07389967
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Metastatic
Interventions
Educational Brochure
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 3:51 PM EDT
Terminated Phase 3 Interventional

R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

NCT00992030
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Rituximab, Involved field irradiation
Drug · Radiation
Lead sponsor
Fondazione Michelangelo
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 31, 2026, 3:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

NCT05256641
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Sacramento, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 31, 2026, 3:51 PM EDT
Terminated Phase 1 Interventional

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

NCT01846429
View directory record Official record
Conditions
Tumor, Cancer, Pain, Malignant Solid Tumor, Unresectable Malignant Neoplasm, Hematologic Malignancy, Multiple Myeloma, Lymphoma, Neoplasm Metastasis
Interventions
Sodium Bicarbonate
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 31, 2026, 3:51 PM EDT
Completed Not applicable Interventional

Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function

NCT03487601
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
transcranial direct current stimulation, sham transcranial direct current stimulation
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 31, 2026, 3:51 PM EDT